Where Werewolf Therapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
Werewolf Therapeutics (NASDAQ:HOWL) has received mixed ratings from 7 analysts over the past three months, with a majority being bullish. The average 12-month price target is $13.71, slightly down from the previous $14.00. The company faces challenges with a significant revenue decline but shows strong net margin, ROE, and ROA compared to industry averages.
June 26, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Werewolf Therapeutics has received mixed ratings from analysts, with a majority being bullish. The average 12-month price target is $13.71, slightly down from $14.00. The company faces significant revenue decline but shows strong net margin, ROE, and ROA compared to industry averages.
The mixed analyst ratings and slight decrease in the average price target suggest a neutral short-term impact. However, the company's strong financial metrics in net margin, ROE, and ROA provide a positive outlook, balancing the negative impact of revenue decline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100